Privileged scaffolds in lead generation

Expert Opinion on Drug Discovery

Volumn 10, Issue 7, 2015, Pages 781-790

  Zhao, Hongyu ^a   Dietrich, Justin ^a  

^a ABBVIE INC   (United States)

Author keywords

Binding warheads; High throughput screening; Multiple ligands; Privileged scaffold; Protein protein interactions

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE INHIBITOR; BETA LACTAM; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIGAND; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; QUINOLINE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; PROTEIN BINDING;

BINDING AFFINITY; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; METAL BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; DRUG DEVELOPMENT; PROCEDURES;

DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; PROTEIN BINDING;

EID: 84932165934     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1041496     Document Type: Review

References (57)

1. Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystin antagonists. J Med Chem 1988;31:2235-46
2. Jörg E, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 2014;13:577-87
3. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719-40
4. Vogt I, Mestres J. Drug-target networks. Mol Inf 2010;29:10-14
5. Paolini GV, Shapland RH, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24:805-15
6. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
7. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25:1119-26
8. Mestres J, Gregori-Puigjane E, Valverde S, et al. The topology of drugtarget interaction networks: implicit dependence on drug properties and target families. Mol BioSyst 2009;5:1051-7
9. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19
10. Pereira DA, Williams JA. Origin and evolution of high throughput screening. Brit J Pharmacol 2007;152:53-61
11. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6:211-19
12. Djuric SW, Akritopoulou-Zanze I, Cox PB, et al. Compound collection enhancement and paradigms for highthroughput screening- an update. Ann Rep Med Chem 2010;45:409-28
13. Savchuk NP, Tkachenko SE, Balakin KV. Strategies for the design of pGPCR-targeted libraries. Strategies for the Design of pGPCR-targeted Libraries. In: Rognan D, editor. Ligand design for G protein-coupled receptors. Wiley-VCH; 2006. p. 137-63
14. Akritopoulou-Zanze I, Hajduk P. Kinase targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 2009;14:291-7
15. Whittaker M. Discovery of protease inhibitors using targeted libraries. Curr Opin Chem Biol 1998;2:386-96
16. Gregori-Puigjane E, Mestres J. Designing chemical libraries directed to nuclear receptors. Nuclear Receptors and Drug Targets. Wiley-VCH; 2008. p. 469-88
17. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010;14:347-61
18. Nammalwar B, Bunce RA. Recent syntheses of 1,2,3,4-tetrahydroquinolines, 2,3-dihydro-4(1H)-quinolones and 4 (1H)-quinolinones using domino reactions. Molecules 2014;19:204-32
19. Traxler P, et al. Tyrosine Kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512
20. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999;82:195-206
21. Meijer L. Rocovitine and other purines as kinase inhibitors: from starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-25
22. Vesely J, Havliceh L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogs. Eur J Biochem 1994;224:771-86
23. Tommasi R, Cornella I. Focused libraries: the evolution in strategy from large-diversity libraries to the focused library approach. Exploiting Chemical Diversity for Drug Discovery. RSC; Cambridge, UK: 2006
24. An JT, Abagyan R. Pocketome via comprehensive identification and classification of ligand binding envelopes. Mol Cell Proteomics 2005;4:752-61
25. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998;280:1-9
26. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 1995;267:383-6
27. Hu Z, Ma B, Wolfson H, Nussinov R. Conservation of polar residues as hot spots at protein interfaces. Proteins 2000;39:331-42
28. Ma B, Elkayam T, Wolfson H, Nussinov R. Protein-protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci USA 2003;100:5772-7
29. Kozakov D, Hall DR, Gwo-Yu C, et al. Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci 2011;108:13528-33
30. Carbonell P, Nussinov R, del Sol A. Energetic determinants of protein binding specificity: Insights into protein interaction networks. Proteomics 2009;9:1744-53
31. Wenxing G, Wisniewski JA, Ji H. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett 2014;24:2546-54
32. Ding K, Lu Y, Nikolovska-Colesdka Z, Wang SJ. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005;127:10130-1
33. Popowicz GM, Czarna A, Wolf S, et al. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010;9:1104-11
34. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
35. Morphy R, Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov Today 2007;12:156-60
36. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struc Biol 2006;16:127-36
37. Cohen P. Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-15
38. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92
39. Frantz S. Drug discovery: playing dirty. Nature 2005;437:942-3
40. Morphy JR, Harris CJ. Designing multitarget drugs. RSC; Cambridge, UK: 2012
41. O'Boyle NM, Pollock JK, Carr M, et al. b-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand. J Med Chem 2014;57:9370-82
42. Johnson DS, Weerapana E, Cravatt BF. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Fut Med Chem 2010;2:949-64
43. Miller Rand M, Paavilainen VO, Krishnan S, et al. Electrophilic fragmentbased design of reversible covalent kinase inhibitors. J Am Chem Soc 2013;135:5298-301
44. Liu Q, Sabnis Y, Zhao Z, et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 2013;20:146-59
45. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009;52:1231-46
46. Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307-17
47. Bugg T. Hydroxamic acids: a unique family of chemicals with multiple biological activities. Springer Berlin Heidelberg; 2014
48. Fernandez D, Pallares I, Covaleda G, et al. Metallocarboxypeptidases and their inhibitors: recent developments in biomedically relevant protein and organic ligands. Curr Med Chem 2013;20:1595-608
49. Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904-27
50. von Nussbaum F, Brands M, Hinzen B, et al. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Intl Ed 2006;45:5072-129
51. Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Boron containing compounds as protease inhibitors. Chem Rev 2012;112:4156-220
52. Hoeger B, Köhn M. Strategies for designing specific protein tyrosine phosphatase inhibitors and their intracellular activation. Concepts and case studies in chemical biology. Wiley VCH; 2014
53. Santos MA, Marques SM, Chaves S. Hydroxypyridinones as "privileged" chelating structures for the design of medicinal drugs. Coordin Chem Rev 2012;256:240-59
54. Polanski J, Kurczyk A, Bak A, Musiol R. Privileged structures-dream or reality: preferential organization of azanaphthalene scaffold. Curr Med Chem 2012;19:1921-45
55. Hu Y, Bajorath J. High-resolution view of compound promiscuity. F1000Res 2013;2:144-53
56. Cox PB, Gregg RJ, Vasudevan A. Abbott physicochemical tiering (APT)-a unified approach to HTS triage. Bioorg Med Chem 2012;20:4564-73
57. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90